HK1112627A1 - - Google Patents

Info

Publication number
HK1112627A1
HK1112627A1 HK08108251.9A HK08108251A HK1112627A1 HK 1112627 A1 HK1112627 A1 HK 1112627A1 HK 08108251 A HK08108251 A HK 08108251A HK 1112627 A1 HK1112627 A1 HK 1112627A1
Authority
HK
Hong Kong
Application number
HK08108251.9A
Inventor
Rolf Bohlmann
Dieter Bittler
Hermann Kuenzer
Peter Esperling
Muhn H Hans-Peter
Fritzemeier K Karl-Heinrich
Ulrike Fuhrmann
Katja Prelle
Steffen Borden Frueher Kurz
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36087369&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1112627(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of HK1112627A1 publication Critical patent/HK1112627A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/008—3 membered carbocyclic rings in position 15/16

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK08108251.9A 2004-12-30 2008-07-25 HK1112627A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004063864A DE102004063864A1 (de) 2004-12-30 2004-12-30 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
PCT/EP2005/014205 WO2006072467A1 (de) 2004-12-30 2005-12-30 18-methyl-19-nor-17-pregn-4-en-21,17-carbolactone, sowie diese enthaltende pharmazeutische präparate

Publications (1)

Publication Number Publication Date
HK1112627A1 true HK1112627A1 (es) 2008-09-12

Family

ID=36087369

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08108251.9A HK1112627A1 (es) 2004-12-30 2008-07-25

Country Status (33)

Country Link
US (1) US20090029953A1 (es)
EP (1) EP1831240B8 (es)
JP (1) JP5043681B2 (es)
KR (1) KR20070093443A (es)
CN (1) CN101128476B (es)
AR (1) AR052657A1 (es)
AU (1) AU2005324055A1 (es)
BR (1) BRPI0518533A2 (es)
CA (1) CA2594171C (es)
CR (1) CR9223A (es)
CY (1) CY1109498T1 (es)
DE (2) DE102004063864A1 (es)
DK (1) DK1831240T3 (es)
EA (1) EA014325B1 (es)
ES (1) ES2331322T3 (es)
GT (1) GT200500394A (es)
HK (1) HK1112627A1 (es)
IL (1) IL184288A (es)
MX (1) MX2007008074A (es)
MY (1) MY145904A (es)
NO (1) NO20073257L (es)
NZ (1) NZ556150A (es)
PA (1) PA8658401A1 (es)
PE (2) PE20100736A1 (es)
PL (1) PL1831240T3 (es)
PT (1) PT1831240E (es)
RS (1) RS51128B (es)
SI (1) SI1831240T1 (es)
TW (1) TW200635942A (es)
UA (1) UA90496C2 (es)
UY (1) UY29320A1 (es)
WO (1) WO2006072467A1 (es)
ZA (1) ZA200706254B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006030416A1 (de) * 2006-06-29 2008-01-03 Bayer Schering Pharma Ag 18-Methyl-19-nor-androst-4-en-17,17-spiroether (18-Methyl-19-nor-20-spirox-4-en-3-one) sowie diese enthaltende pharmazeutische Präparate
DE102007027637A1 (de) 2007-06-12 2008-12-18 Bayer Schering Pharma Aktiengesellschaft 17ß-Cyano-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007027636A1 (de) 2007-06-12 2008-12-18 Bayer Schering Pharma Aktiengesellschaft 17ß-Cyano-18a-homo-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007027635A1 (de) * 2007-06-12 2008-12-18 Bayer Schering Pharma Aktiengesellschaft 17ß-Cyano-19-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007063500A1 (de) * 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 17-(1'-Propenyl)-17-3'-oxidoestra-4-en-3-on-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007063496A1 (de) * 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 15,16-Methylen-17-(1'-propenyl)-17-3'-oxidoestra-4-en-3-on-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007063503A1 (de) 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-19-nor-21-carbonsäure-Steroid y-Lacton-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007063501A1 (de) * 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 15, 16-Methylen-17-hydroxy-19-nor-21-carbonsäure-Steroid y-Lacton-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007063498A1 (de) * 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 15,16-Methylen-steroid-17,17-Lactol-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007063495A1 (de) * 2007-12-29 2009-09-17 Bayer Schering Pharma Aktiengesellschaft 19-Nor-Steroidderivate mit einer 15α,16α-Methylengruppe und einem gesättigten 17,17-Spirolactonring, deren Verwendung sowie diese Derivate enthaltende Arzneimittel
DE102007063499A1 (de) 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft Steroid-17,17-Lactol-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
WO2009111574A2 (en) * 2008-03-05 2009-09-11 Evestra, Inc. BISMETHYLENE-17α CARBOLACTONES AND RELATED USES
DE102008026793A1 (de) 2008-06-02 2009-12-03 Bayer Schering Pharma Aktiengesellschaft C-Ring-substituierte Pregn-4-en-21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
CN101623287B (zh) * 2008-07-07 2012-02-08 天津金耀集团有限公司 一种屈螺酮类似物的治疗更年期综合症的药物组合物
US8222237B2 (en) * 2008-11-25 2012-07-17 Evestra, Inc. Progestational 3-(6,6-ethylene-17B-hydroxy-3-oxo-17A-pregna-4-ene-17A-yl)propionic acid G-lactones
WO2010066349A1 (de) * 2008-12-12 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Verwendung von 17beta-cyano-19-androst-4-en-derivaten zur herstellung eines arzneimittels in depot-form zur parenteralen anwendung sowie depot-arzneimittel enthaltend 17beta-cyano-19-androst-4-en-derivate zur parenteralen anwendung
WO2010066355A1 (de) * 2008-12-12 2010-06-17 Bayer Schering Pharma Aktiengesellschaft VERWENDUNG VON 17β- CYANO-19-NOR-ANDROST-4-EN-DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS IN DEPOT-FORM ZUR PARENTERALEN ANWENDUNG SOWIE DEPOT-ARZNEIMITTEL ENTHALTEND 17β-CYANO-19-NOR-ANDROST-4-EN-DERIVATE ZUR PARENTERALEN ANWENDUNG
WO2010066354A1 (de) * 2008-12-12 2010-06-17 Bayer Schering Pharma Aktiengesellschaft VERWENDUNG VON 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS IN DEPOT-FORM ZUR PARENTERALEN ANWENDUNG SOWIE DEPOT-ARZNEIMITTEL ENTHALTEND 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATE ZUR PARENTERALEN ANWENDUNG
WO2012059594A1 (en) 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959322A (en) * 1960-09-22 1976-05-25 Herchel Smith Synthesis of 13-alkyl-gon-4-ones
DE3022337A1 (de) * 1980-06-11 1982-01-07 Schering Ag Berlin Und Bergkamen, 1000 Berlin Praeparate zur kontrazeption und zur behandlung gynaekologischer stoerungen
DE3402329A1 (de) * 1984-01-20 1985-08-01 Schering AG, 1000 Berlin und 4709 Bergkamen 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
FR2739029B1 (fr) * 1995-09-21 1997-11-21 Roussel Uclaf Nouvelle application therapeutique des composes antimineralo-corticoides
DE19651000A1 (de) * 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone

Also Published As

Publication number Publication date
TW200635942A (en) 2006-10-16
PT1831240E (pt) 2009-10-22
PL1831240T3 (pl) 2010-01-29
DK1831240T3 (da) 2009-11-23
EP1831240B8 (de) 2010-02-17
AU2005324055A1 (en) 2006-07-13
IL184288A0 (en) 2007-10-31
RS51128B (sr) 2010-10-31
CA2594171C (en) 2012-10-16
US20090029953A1 (en) 2009-01-29
PE20100736A1 (es) 2010-12-03
EA200701239A1 (ru) 2007-12-28
EP1831240B1 (de) 2009-07-15
MY145904A (en) 2012-05-15
KR20070093443A (ko) 2007-09-18
ES2331322T3 (es) 2009-12-29
NZ556150A (en) 2011-02-25
CA2594171A1 (en) 2006-07-13
JP5043681B2 (ja) 2012-10-10
CN101128476B (zh) 2011-02-09
JP2008526709A (ja) 2008-07-24
CR9223A (es) 2007-11-23
CY1109498T1 (el) 2014-08-13
NO20073257L (no) 2007-08-29
EA014325B1 (ru) 2010-10-29
EP1831240A1 (de) 2007-09-12
IL184288A (en) 2011-06-30
GT200500394A (es) 2006-08-01
ZA200706254B (en) 2008-12-31
SI1831240T1 (sl) 2009-12-31
BRPI0518533A2 (pt) 2008-11-25
PA8658401A1 (es) 2006-08-03
CN101128476A (zh) 2008-02-20
DE502005007723D1 (de) 2009-08-27
PE20060853A1 (es) 2006-09-15
MX2007008074A (es) 2008-03-10
UA90496C2 (ru) 2010-05-11
UY29320A1 (es) 2006-07-31
DE102004063864A1 (de) 2006-07-13
WO2006072467A1 (de) 2006-07-13
AR052657A1 (es) 2007-03-28

Similar Documents

Publication Publication Date Title
BE2024C508I2 (es)
BE2022C549I2 (es)
BE2024C511I2 (es)
BE2020C513I2 (es)
BE2020C517I2 (es)
BE2019C540I2 (es)
BE2019C548I2 (es)
BE2018C045I2 (es)
BE2017C027I2 (es)
BE2017C023I2 (es)
BE2017C002I2 (es)
BE2016C067I2 (es)
BE2016C014I2 (es)
BE2015C041I2 (es)
BE2015C038I2 (es)
BE2015C066I2 (es)
BE2015C014I2 (es)
BE2019C535I2 (es)
BE2015C065I2 (es)
IN2006DE04680A (es)
BR122015024347A2 (es)
BRPI0508002A (es)
JP2005081155A5 (es)
BE2016C042I2 (es)
BE2016C035I2 (es)

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20141230